Full Year 2024 Novacyt SA Earnings Call Transcript
Key Points
- Novacyt SA (NVYTF) successfully resolved the DHSC disputes, resulting in a net cash inflow of over GBP7 million.
- The company achieved significant cost savings, reducing OpEx from GBP27 million to GBP21 million, delivering synergies ahead of schedule.
- Reproductive healthcare products experienced a 26% year-on-year growth, driven by regulatory approvals and market expansion.
- The company maintained a strong gross margin of over 60%, with the primary design business delivering a gross margin of over 80%.
- Novacyt SA (NVYTF) is investing over GBP2 million into R&D to drive organic growth, with new product launches expected in H2 2025.
- The company reported a loss after tax of just under GBP42 million for 2024.
- Trade receivables decreased significantly due to the write-off of the DHSC invoice for GBP24 million.
- The company faced exceptional costs totaling around GBP21 million, including charges related to the Yourgene acquisition and DHSC dispute.
- Primary design business revenue appeared to decline year-on-year, partly due to the absence of COVID-related sales.
- The company has been relatively quiet in terms of strategic updates, leading to some investor concerns about future growth plans.
Good morning and welcome to the Novacyt SA for your results investor presentation. Throughout recorded presentation, investors will be in listen only mode. Questions are encouraged and they can be submitted at any time by the Q&A tab situated on the right hand corner of the screen. Just simply type in your questions and press send.
The company may not be in a position to answer every question it received in the meeting itself, but the company can review the questions submitted today and publish responses where it's appropriate to do so. Before we begin, I'd like to submit the following poll, and for the benefit of those joining us from France.(foreign language) I'd now like to hand you Lyn Rees, CEO good morning, sir.
Good morning and thank you. And, good morning, everyone. We really appreciate you joining us today, and we look forward to giving you the latest update from the Novacyt Group. Presenting today is myself, Lyn Rees, Chief Exec, and Steve, our CFO, and we're just
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
